BACKGROUND: Long-term impact of drug resistance in perinatally infected children and adolescents living with HIV (CALWH) is poorly understood. We determined drug resistance and examined its long-term impact on failure and mortality in Kenyan CALWH failing first-line non-nucleoside reverse transcriptase inhibitor-based antiretroviral therapy (ART). SETTING: Academic Model Providing Access to Healthcare, western Kenya. METHODS: Participants were enrolled in 2010-2013 (timepoint 1) and a subsample re-enrolled after 4-7 years (timepoint 2). Viral load (VL) was performed on timepoint 1 samples, with genotyping of those with detectable VL. Primary endpoints were treatment failure (VL >1000 copies/mL) at and death before timepoint 2. Multinomial regression analysis was used to characterize resistance effect on death, failure, and loss-to-follow-up, adjusting for key variables. RESULTS: The initial cohort (n = 480) was 52% (n = 251) female, median age 8 years, median CD4% 31%, 79% (n = 379) on zidovudine/abacavir + lamivudine + efavirenz/nevirapine for median 2 years. Of these, 31% (n = 149) failed at timepoint 1. Genotypes at timepoint 1, available on n = 128, demonstrated 93% (n = 119) extensive resistance, affecting second line. Of 128, 22 failed at timepoint 2, 17 died, and 32 were lost to follow-up before timepoint 2. Having >5 resistance mutations at timepoint 1 was associated with higher mortality [relative risk ratio (RRR) = 8.7, confidence interval (CI) 2.1 to 36.3] and loss to follow-up (RRR = 3.2, CI 1.1 to 9.2). Switching to second line was associated with lower mortality (RRR <0.05, CI <0.05 to 0.1) and loss to follow-up (RRR = 0.1, CI <0.05 to 0.3). CONCLUSION: Extensive resistance and limited switch to second line in perinatally infected Kenyan CALWH failing first-line ART were associated with long-term failure and mortality. Findings emphasize urgency for interventions to sustain effective, life-long ART in this vulnerable population.
BACKGROUND: Long-term impact of drug resistance in perinatally infected children and adolescents living with HIV (CALWH) is poorly understood. We determined drug resistance and examined its long-term impact on failure and mortality in Kenyan CALWH failing first-line non-nucleoside reverse transcriptase inhibitor-based antiretroviral therapy (ART). SETTING: Academic Model Providing Access to Healthcare, western Kenya. METHODS: Participants were enrolled in 2010-2013 (timepoint 1) and a subsample re-enrolled after 4-7 years (timepoint 2). Viral load (VL) was performed on timepoint 1 samples, with genotyping of those with detectable VL. Primary endpoints were treatment failure (VL >1000 copies/mL) at and death before timepoint 2. Multinomial regression analysis was used to characterize resistance effect on death, failure, and loss-to-follow-up, adjusting for key variables. RESULTS: The initial cohort (n = 480) was 52% (n = 251) female, median age 8 years, median CD4% 31%, 79% (n = 379) on zidovudine/abacavir + lamivudine + efavirenz/nevirapine for median 2 years. Of these, 31% (n = 149) failed at timepoint 1. Genotypes at timepoint 1, available on n = 128, demonstrated 93% (n = 119) extensive resistance, affecting second line. Of 128, 22 failed at timepoint 2, 17 died, and 32 were lost to follow-up before timepoint 2. Having >5 resistance mutations at timepoint 1 was associated with higher mortality [relative risk ratio (RRR) = 8.7, confidence interval (CI) 2.1 to 36.3] and loss to follow-up (RRR = 3.2, CI 1.1 to 9.2). Switching to second line was associated with lower mortality (RRR <0.05, CI <0.05 to 0.1) and loss to follow-up (RRR = 0.1, CI <0.05 to 0.3). CONCLUSION: Extensive resistance and limited switch to second line in perinatally infected Kenyan CALWH failing first-line ART were associated with long-term failure and mortality. Findings emphasize urgency for interventions to sustain effective, life-long ART in this vulnerable population.
Authors: Luke C Swenson; Jeong Eun Min; Conan K Woods; Eric Cai; Jonathan Z Li; Julio S G Montaner; P Richard Harrigan; Alejandro Gonzalez-Serna Journal: AIDS Date: 2014-05-15 Impact factor: 4.177
Authors: Shirley Lecher; Jason Williams; Peter N Fonjungo; Andrea A Kim; Dennis Ellenberger; Guoqing Zhang; Christiane Adje Toure; Simon Agolory; Georgette Appiah-Pippim; Suzanne Beard; Marie Yolande Borget; Sergio Carmona; Geoffrey Chipungu; Karidia Diallo; Marie Downer; Dianna Edgil; Holly Haberman; Mackenzie Hurlston; Steven Jadzak; Charles Kiyaga; William MacLeod; Boniface Makumb; Hellen Muttai; Christina Mwangi; Jane W Mwangi; Michael Mwasekaga; Mary Naluguza; Lucy W Ng'Ang'A; Shon Nguyen; Souleymane Sawadogo; Katrina Sleeman; Wendy Stevens; Joel Kuritsky; Shannon Hader; John Nkengasong Journal: MMWR Morb Mortal Wkly Rep Date: 2016-12-02 Impact factor: 17.586
Authors: Rachel C Vreeman; Winstone M Nyandiko; Hai Liu; Wanzhu Tu; Michael L Scanlon; James E Slaven; Samuel O Ayaya; Thomas S Inui Journal: AIDS Behav Date: 2015-04
Authors: M H W Huibers; C Kityo; R S Boerma; E Kaudha; K C E Sigaloff; S N Balinda; S Bertagnolio; R Nakanjako; P Mugyenyi; J C J Calis; M Boele van Hensbroek; T F Rinke de Wit Journal: J Antimicrob Chemother Date: 2019-10-01 Impact factor: 5.790
Authors: Helen Bell Gorrod; Richard Court; Michael Schomaker; Gary Maartens; Richard A Murphy Journal: J Acquir Immune Defic Syndr Date: 2020-05-01 Impact factor: 3.771
Authors: Julie Kadima; Elizabeth Patterson; Margaret Mburu; Cinthia Blat; Margaret Nyanduko; Elizabeth Anne Bukusi; Craig Cohen; Patrick Oyaro; Lisa Abuogi Journal: PLoS One Date: 2018-11-09 Impact factor: 3.240
Authors: Ragna S Boerma; T Sonia Boender; Anton P Bussink; Job C J Calis; Silvia Bertagnolio; Tobias F Rinke de Wit; Michael Boele van Hensbroek; Kim C E Sigaloff Journal: Clin Infect Dis Date: 2016-09-22 Impact factor: 9.079